A
AOA
A biotech company focused on early-stage cancer detection
About AOA
AOA Dx is a cutting-edge startup that operates in the healthcare technology sector, specifically focusing on early cancer detection. The company has developed GlycoLocate™, an Artificial Intelligence (AI) enabled platform that leverages the power of data science to detect cancer at its earliest stages. This innovative technology is the first of its kind to utilize tumor marker gangliosides, a new class of biomarkers, to provide unprecedented insights into early cancer detection.
The company primarily serves healthcare providers and patients, with a particular emphasis on women's health. AOA Dx's business model revolves around the research, development, and commercialization of its proprietary technology. The company generates revenue by licensing its technology to healthcare providers and institutions, who then use it to enhance their diagnostic capabilities and patient care.
AOA Dx is a team of seasoned industry experts and entrepreneurs who are dedicated to bringing impactful and cost-effective medical technologies to the market. The company is committed to innovation in women's health and is at the forefront of pioneering the field of glycolipids.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Denver, United States
- Employees
- 55
- Open positions
- None listed
- Dealroom signal
- 59.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biomarkers, Core AI, Spinout, AI Applications, YC S21, DT and LS
- Technology
- Artificial Intelligence, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Oct 2025 | $0 | — | Undisclosed | ↗ |
| EARLY VC✓Equity / VC | Oct 2023 | $17M | $68M | Y Combinator · LabCorp · Good Growth Capital · FemHealth Ventures | ↗ |
Growth signals
Latest recorded traffic for AOA is 6.3K monthly website visits, up 6.8% over the last three months. AOA's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed11 investors entered at this stage
Y Combinator
Joyance Partners
Launchpad Venture Group- SASidecar Angels
TBD Angels- KSKYTO Technology & Life Science
Beacon Angels
AlleyCorp
Pioneer Fund
Avestria Ventures
The Helm
Series A7 investors entered at this stage
Tencent
Olive Tree Capital
RHIA Ventures
LabCorp
Good Growth Capital
FemHealth Ventures
RH Capital
Other known investors12 additional known investors
McGill University
Astia- BGBantam Group
Cavendish Impact Capital
Emmeline Ventures
Kube VC
LongeVC
Oxonian Ventures
Sharon Vosmek
Undeterred Capital
VU Venture Partners
Walnut Venture Associates
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AOA on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AOA’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.